1.- Punzalan RC, Hillery CA, Montgomery RR, et al. Low molecular weight heparin in thrombotic desease in children and adolescents. J Pedriatr Hematol Oncol 2000; 22: 137-42.

2.- Dix D, Andrew M, Marzinoto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pedriatr 2000; 136: 439-45.

3.- Kuhle S, Mitchell L, Massicotte P, et al. Hemostatic disorders of newborn. In: Taeusch HW, Ballard RA, Gleason CA, editors. Avery’s Diseases of the Newborn. Philadelphia: Saunders; 2004. p. 1145-79.

4.- Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during childhood. Blood 1992; 80; 1998-2005.

5.- Massicotte P, Julian JA, Gent M, et al. An open-label randomised controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003; 109: 85-92.

6.- Stefan Kuhle, Barbara Koloshuk, Velma Marzimotto, et al. A cross-sectional study evaluating post-thombotic síndrome in children. Thromb Res 2003; 111: 227-233.

7.- Newall F, Savota H, Campbell J, et al. Anticoagulation clinics for children achieve improved warfarin management. Throm Res 2004; doi: 10.1016/j.thromres.2004.03.018.